TP53 and leukemia: Indeed, genetic modifications of MSC in the tumor microenvironment have been reported in hematologic diseases like leukemia, with various structural and/or numerical chromosome aberration [53] and carcinoma, e.g., breast cancer, with P53, PTEN, and WFDC1 mutations [54].